Big pharma wants you
Article Abstract:
A class of investors known as the strategic corporate venture capitalists, who are actually big pharmas, biopharmas and medical device companies, are in great need of unrealistically powerful internal R&D machines to keep their pipelines pumping out innovative new products to replenish expiring patents. Small startup life science companies can benefit from such companies that are willing to invest in small startups through mergers, acquisitions and in-licensed technologies and products to accomplish their objective.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
The rise of venture capital and biotechnology in the US and Europe
Article Abstract:
Venture capital (VC) funds range in size from about $20 million to billion of dollars and in return for investments in young, high-risk companies, the VC firm acquires significant equity positions in the these companies and has the potential to realize large returns on its investment when these companies begin trading shares on public markets or are acquired. Biotechnology investment in Europe and the United States are funded by the VC.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
Term sheet trends in the venture capital market
Article Abstract:
A term sheet referred to as letters of intent is a summary of the principal terms on which an investor is willing to make an investment in a company. Term sheet provides the opportunity for an investor to clearly set out the terms and conditions needed to make a deal work.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Proactive accounting: a key factor in the success of biotechnology startups. Strategic HR for today's biotechnology companies
- Abstracts: Disclosure quality and the excess value of diversification. Discussion of accounting discretion in fair value estimates: an examination of SFAS 142 goodwill impairments
- Abstracts: Biotech's knowledge trust. Probity gone nuts
- Abstracts: Breaching the skin's barrier to drugs. A peptide chaperone for transdermal drug delivery. Transdermal protein delivery by a coadministered peptide identified via phase display